查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1983709

肿瘤体内CRO市场：依动物模型、给药途径、治疗方法及最终用户划分－2026年至2032年全球市场预测

Oncology Based In-Vivo CRO Market by Animal Model, Route Of Administration, Therapeutic Modality, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肿瘤领域的体内 CRO 市场价值将达到 15.7 亿美元，到 2026 年将成长到 17.6 亿美元，到 2032 年将达到 34.3 亿美元，复合年增长率为 11.76%。

主要市场统计数据
基准年 2025 15.7亿美元
预计年份：2026年 17.6亿美元
预测年份 2032 34.3亿美元
复合年增长率 (%) 11.76%

这凸显了体内肿瘤学研究的策略必要性，以加速转换突破，降低研发失败率，并加强相关人员之间的临床前决策。

肿瘤学研究领域依然复杂多变，这要求管理者需要简洁明了、切实可行的洞察，以便做出直接影响后续临床结果的临床前决策。本执行摘要整合了营运、科学和策略观点，旨在明确体内研究能力至关重要的领域、实验设计选择如何影响转化意义，以及应指导服务和伙伴关係投资的组织优先事项。

在免疫工程、精确建模、整合分析和协作生态系统的驱动下，不断发展的临床前范式正在重塑肿瘤学体内研究的实践。

临床前研究环境正经历一场变革，肿瘤学计画的规划和实施方式也随之改变。免疫工程的进步以及人源化和基因定义的动物模型日益成熟，提高了实验机制的精确度。同时，包括基于机器学习的影像分析和纵向生物标记追踪在内的综合分析方法，正在将复杂的体内资料集转化为更清晰的「启动/停止」讯号。这些技术进步也推动了组织架构的变革，例如药物研发、转换和临床团队之间更紧密的合作，以便更早就具有临床意义的终点达成共识。

评估新的贸易壁垒对肿瘤体内服务提供和全球研究的持续性、营运、成本、监管和创新所产生的连锁影响。

新的贸易政策和关税体係正在产生一系列复杂的下游影响，远不止于直接采购成本。前置作业时间、供应链碎片化和库存持有成本增加。实际上，这些运作摩擦往往会导致研究启动延迟、实验週期缩短以及需要替代采购方式，所有这些都会降低肿瘤专案进度安排的可预测性。

透过分析模型选择、给药途径、治疗方法和最终用户人口统计特征，我们旨在揭示微妙的需求因素及其对体内肿瘤学实验设计的影响。

稳健的细分观点能够清楚阐明科学和商业性优先事项的分歧所在，以及如何调整资源分配以契合实验目标。在考虑动物模型时，研究通常分为小鼠模型和非小鼠模型。小鼠模型包括基因修饰小鼠模型、免疫原性同基因模型和小鼠异种移植模型，而非小鼠模型则包含犬、兔子和大鼠模型。每种模型在免疫学、药理学和毒理学终点方面各有优势，这直接指南研究设计决策和供应商选择。因此，专案经理必须根据作用机制和所考虑的转换挑战来选择合适的模型。

区域比较趋势突显了全球肿瘤研究中心明确的策略重点、供应链现状、监管环境和合作研究机会。

区域趋势影响着能力建构的发展方式、供应链的建构方式以及科学合作最活跃的领域。美洲地区汇聚了转化医学专长、强大的生物技术生态系统以及完善的免疫肿瘤学基础设施，这有利于开展高通量、以转化医学为导向的体内研究项目，这些项目需要快速迭代并与临床研发管线紧密结合。该地区对监管法规的熟悉程度以及活跃的创业投资活动，支持申办方和服务供应商之间建立灵活的伙伴关係，同时也强调可重复性和文件记录的重要性。

服务供应商之间的竞争定位和能力差异化，重点在于专业动物模型、技术整合、资讯服务和策略合作伙伴关係。

肿瘤生物医学检测领域的竞争格局日益取决于服务能力的广度、专业知识的深度以及将资讯服务与实验室运作相结合的能力。能够同时拥有先进的小鼠模型、检验的非小鼠毒性测试平台以及严谨的给药途径专业知识的服务商，可以为转化医学计画提供差异化的端到端解决方案。同样重要的是，服务商还需具备满足特定治疗方式需求的能力，例如免疫查核点抑制剂的免疫治疗终点检测，以及激酶抑制剂和小分子药物的药物动力学和标靶结合检测。

为高阶主管提供可操作的策略建议，以建立业务永续营运、优先考虑科学投资并加速从临床前肿瘤学计画中创造转化价值。

产业领导者应采取多管齐下的策略方法，在确保业务连续性的同时，充分利用科学进步。首先，应实现检验和库存策略多元化，以减少对动物品系、特殊试剂和关键设备等单一故障点的依赖。确保拥有可靠的替代供应商，并维持关键组件的滚动库存，即使在国际贸易或物流中断的情况下，也能确保研究进度不受影响。其次，应优先投资于能反映治疗重点领域的模型组合。例如，均衡地组合基因修饰小鼠模型、免疫原性同源模型和关键的非小鼠毒性模型，将确保能够应对各种转化医学挑战。

透过结合关键相关人员的信息、实验室检验、营运审计和精心挑选的第二手资料，采用稳健的三角测量方法，可以得出严谨且可操作的结论。

本执行报告的调查方法结合了定性一手调查、有针对性的营运检验和精心挑选的二手证据，确保研究结果严谨且具有直接适用性。一手资讯是透过对资深转化科学研究人员、营运经理和采购专家进行结构化访谈收集的，旨在获取关于模型选择、供应商绩效和物流挑战的第一手观点。除了访谈外，还进行营运审计和实验室访问，以检验工作流程、模型培育计划和资料收集过程，从而对报告的能力进行现场确认。

透过整合营运洞察、科学趋势和策略意义，得出明确的结论，从而指导经营团队决策，并优化肿瘤学领域的短期研究计画。

这项综合分析凸显了肿瘤学非临床研究中的几个永恆真理：模型选择至关重要，运作韧性是转化研究信心的基石，而整合的资料管理实践则能缩短从实验中观察到专案决策的流程。免疫肿瘤学和标靶治疗的科学进步需要针对个别情况优化的体内策略，这些策略应反映药物的作用机制、给药途径和临床终点。同时，从贸易措施到区域监管差异等外部压力，正迫使申办方和提供者投资于多元化的资源取得、在地化能力建设以及更完善的合约框架。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：肿瘤学领域动物模型体内CRO市场

  • 老鼠
    • 基因改造小鼠模型
    • 具有免疫能力的相关谱系
    • 小鼠异种移植模型
  • 非滑鼠
    • 狗
    • 兔子
    • 鼠

第九章：肿瘤领域体内CRO市场：依给药途径划分

  • 静脉
  • 口服
  • 皮下

第十章：肿瘤治疗方法体内CRO市场

  • 化疗
  • 免疫疗法
    • 查核点抑制剂
    • 单株抗体
  • 分子标靶治疗
    • 激酶抑制剂
    • 小分子抑制剂

第十一章：肿瘤体内CRO市场：依最终用户划分

  • 学术机构和研究机构
  • CRO
  • 製药公司

第十二章：肿瘤领域体内CRO市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：肿瘤领域体内CRO市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：肿瘤领域体内CRO市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国肿瘤领域体内CRO市场

第十六章：中国肿瘤领域体内CRO市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bioanalytical Systems, Inc.
  • Celerion, Inc.
  • Champion Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • Explora BioLabs, Inc.
  • Frontage Laboratories, Inc.
  • GenScript Biotech Corporation
  • GenScript ProBio Co., Ltd.
  • Inotiv, Inc.
  • JSR Life Sciences Corporation
  • KCR SA
  • Laboratory Corporation of America Holdings
  • Living Tumor Laboratory, Inc.
  • MPI Research, Inc.
  • Oncodesign SA
  • Parexel International Corporation
  • PRA Health Sciences, Inc.
  • Syneos Health, Inc.
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory, Inc.
  • Toxikon Corporation
  • Translational Drug Development, Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-FF012EDC38C0

The Oncology Based In-Vivo CRO Market was valued at USD 1.57 billion in 2025 and is projected to grow to USD 1.76 billion in 2026, with a CAGR of 11.76%, reaching USD 3.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.57 billion
Estimated Year [2026] USD 1.76 billion
Forecast Year [2032] USD 3.43 billion
CAGR (%) 11.76%

Framing the strategic imperative for oncology in-vivo research to accelerate translational breakthroughs, reduce attrition, and strengthen preclinical decision-making across stakeholders

The landscape of oncology research remains complex and dynamic, and executives require concise, actionable intelligence to make preclinical decisions that directly influence downstream clinical outcomes. This executive summary synthesizes operational, scientific, and strategic perspectives to clarify where in-vivo capabilities matter most, how experimental design choices shape translational relevance, and which organizational priorities should guide investment in services and partnerships.

Throughout the report, emphasis is placed on the intersection between scientific rigor and operational resilience. Translational value depends not only on model selection and dosing paradigms but also on supply chain integrity, data fidelity, and regulatory alignment. Consequently, the executive view focuses on practical levers that reduce technical attrition, accelerate validation timelines, and improve reproducibility across multicenter programs. By concentrating on decision points that executives can influence-such as model portfolios, vendor qualification, and integrated data pipelines-this introduction sets the stage for a pragmatic, strategy-forward conversation that informs both near-term actions and medium-term capability building.

The intent is to equip decision-makers with a clear framework for aligning scientific priorities with commercial realities and operational constraints, thereby enabling more predictable and effective progression from preclinical insights to clinical hypotheses.

Evolving preclinical paradigms driven by immunoengineering, precision models, integrated analytics, and collaborative ecosystems that are reshaping oncology in-vivo research practices

The preclinical research environment has been undergoing transformative shifts that are changing how oncology programs are designed and executed. Advances in immunoengineering and the maturation of humanized and genetically defined animal models are improving the mechanistic fidelity of experiments. At the same time, integrated analytics, including machine learning-enabled image analysis and longitudinal biomarker tracking, are turning complex in-vivo datasets into clearer go/no-go signals. These technological evolutions are accompanied by organizational shifts: tighter collaboration between discovery, translational, and clinical teams is enabling earlier alignment on endpoints that matter clinically.

Concurrently, the industry is seeing methodological convergence between in-vivo and ex vivo approaches. Organoid systems and sophisticated co-culture platforms are increasingly used to triage candidates before committing to resource-intensive animal studies, thereby creating a cascade effect that raises the bar for the in-vivo experiments that are performed. Regulatory expectations and reproducibility imperatives are also prompting greater standardization of protocols and metadata capture, leading providers to invest in quality systems and data harmonization. Together, these shifts are not merely incremental; they are reshaping service offerings, partnership models, and the criteria by which translational success is judged.

Assessing the cascading operational, cost, regulatory, and innovation effects of emerging trade barriers on oncology in-vivo service delivery and global research continuity

Emerging trade policies and tariff regimes have introduced a complex set of downstream effects that extend beyond immediate procurement costs. Increased duties and customs scrutiny for imported reagents, specialized animal strains, and critical equipment can lead to longer lead times, fragmented supply chains, and higher inventory carrying costs. In practice, these operational frictions often translate into delayed study starts, compressed experiment windows, and the need for contingency sourcing, all of which erode schedule predictability for oncology programs.

Further, tariffs can alter vendor economics and sourcing decisions, prompting some providers to localize certain functions or to reconfigure service portfolios to rely less on imported components. This reconfiguration can have knock-on effects for model availability, especially for specialized or proprietary strains that are produced in geographically concentrated facilities. In turn, sponsors and service providers face a choice between maintaining tight biological fidelity through original model use or accepting alternative models that may introduce translational risk.

Importantly, the cumulative impact of trade measures also affects collaborative research that depends on cross-border sample transfers or multinational study coordination. To maintain momentum, research leaders must prioritize supply chain transparency, diversify vendor relationships, and incorporate contingency planning into project timelines. When combined with improved forecasting and contractual flexibility, such measures help mitigate the operational uncertainty introduced by evolving tariff environments.

Dissecting model selection, administration routes, therapeutic modalities, and end user segmentation to reveal nuanced demand drivers and experimental design implications for in-vivo oncology

A robust segmentation lens clarifies where scientific and commercial priorities diverge, and how resource allocation should be tailored to experimental intent. When examined by animal model, studies are commonly categorized into murine and non-murine groups; murine models include genetically engineered mouse models, immunocompetent syngeneic models, and mouse xenografts, while non-murine options encompass dog, rabbit, and rat models. Each of these model classes has different strengths for immunology, pharmacology, and toxicology endpoints, which directly guides study design decisions and vendor selection. Thus, portfolio managers should align model choice with the mechanism of action and the translational questions at hand.

Route of administration segmentation-typically intravenous, oral, and subcutaneous-further refines experimental planning. Dosing route influences pharmacokinetics, formulation strategies, and safety assessment, and therefore it must be considered early in preclinical development to ensure clinically relevant exposure. Therapeutic modality segmentation delineates distinct developmental pathways: chemotherapy, immunotherapy, and targeted therapy; within immunotherapy, checkpoint inhibitors and monoclonal antibodies are principal subcategories, and within targeted therapy, kinase inhibitors and small molecule inhibitors define technical approaches. These modality distinctions have operational implications for dosing regimens, biomarker selection, and model suitability.

Finally, end user segmentation-covering academia and research institutes, contract research organizations, and pharmaceutical companies-reveals differing expectations around throughput, documentation rigor, and customization. Academic customers often prioritize exploratory endpoints and method development, whereas pharmaceutical sponsors emphasize regulatory readiness and data traceability. Contract research organizations occupy an intermediary role, balancing standardization with bespoke services to serve both academic and industry clients. Together, these segmentation dimensions create a matrix that should inform capability investments, pricing strategies, and partnership models.

Comparative regional dynamics highlighting distinct strategic priorities, supply chain realities, regulatory landscapes, and collaborative opportunities across global oncology research hubs

Regional dynamics shape how capabilities are developed, how supply chains are structured, and where scientific collaboration is most active. In the Americas, there is a concentration of translational expertise, strong biotech ecosystems, and established infrastructure for immuno-oncology, which encourages high-throughput, translationally focused in-vivo programs that demand rapid iteration and close integration with clinical pipelines. This region's regulatory familiarity and dense venture capital activity support agile partnerships between sponsors and service providers, yet it also places a premium on reproducibility and documentation practices.

In Europe, Middle East & Africa, variations in regulatory frameworks and research funding models create heterogeneity in capability and demand. Institutional collaborations and multi-center academic networks often drive innovation here, and providers frequently need to accommodate a broader spectrum of compliance requirements and language-specific documentation. Supply chain considerations can vary significantly across countries, making regional logistics expertise and local inventory strategies important for maintaining timelines.

Asia-Pacific is characterized by fast-growing research capacity, increasing domestic pharmaceutical R&D, and a rising share of outsourced preclinical work. This region offers opportunities for cost-effective operations, access to diverse biological models, and expanding laboratory infrastructure. However, leaders must navigate differing regulatory expectations, local ethical standards, and the need for robust quality management systems to ensure data generated locally is acceptable to multinational sponsors. Altogether, regional distinctions influence how providers prioritize investments and how sponsors allocate studies to maximize both scientific validity and operational efficiency.

Competitive positioning and capability differentiation among service providers emphasizing specialized animal models, technology integration, data services, and strategic alliances

Competitive dynamics in the oncology in-vivo space are increasingly defined by capability breadth, specialization depth, and the ability to integrate data services with wet-lab operations. Providers that combine access to advanced murine models, validated non-murine toxicology platforms, and rigorous route-of-administration expertise can offer differentiated end-to-end solutions for translational programs. Equally important is the capacity to support modality-specific needs, such as immunotherapy endpoint assays for checkpoint inhibitors or pharmacokinetic and target engagement assays for kinase inhibitors and small molecule programs.

Beyond technical offerings, leading firms are investing in standardized reporting, electronic data capture, and analytics platforms that translate raw experimental outputs into decision-ready intelligence. Strategic alliances and co-development arrangements with discovery organizations are also shaping the competitive landscape, enabling providers to participate earlier in candidate selection and to influence preclinical strategy. Service differentiation is furthermore influenced by geographical reach and supply chain robustness; providers with localized breeding facilities, decentralized reagent sourcing, and clear export/import expertise are more resilient to operational shocks.

Intellectual property considerations and the emergence of specialized contract service verticals-such as immuno-oncology platforms or precision oncology models-create niches that smaller, highly specialized providers can exploit. For sponsors, selecting a partner increasingly involves assessing both technical fit and the provider's ability to adapt protocols, share data transparently, and align around development timelines.

Actionable strategic recommendations for leaders to build operational resilience, prioritize scientific investments, and accelerate translational value from preclinical oncology programs

Industry leaders should adopt a multi-pronged strategic approach to capitalize on scientific advances while safeguarding operational continuity. First, diversify sourcing and inventory strategies to reduce exposure to single-point failures in animal strains, specialized reagents, and critical equipment. Building validated alternative suppliers and maintaining rolling inventory for key components will preserve study schedules when external trade or logistics disruptions occur. Second, prioritize investment in model portfolios that reflect therapeutic focus areas; for example, retain a balanced mix of genetically engineered mouse models, immunocompetent syngeneic systems, and key non-murine toxicology models to cover a broad spectrum of translational questions.

Third, integrate data management and analytics capabilities with laboratory operations to ensure high-quality metadata capture, reproducible protocols, and rapid downstream analysis. Establishing common data standards across internal and external partners reduces ambiguity in interpretation and accelerates decision cycles. Fourth, engage proactively with regulatory and ethical bodies to harmonize expectations for study design, humane use of animals, and data transparency; early engagement mitigates rework and supports cross-border acceptability of data. Finally, invest in talent development and cross-functional teams that bridge discovery, translational science, and operations so that experimental design decisions are aligned with program objectives and commercial imperatives.

Taken together, these measures create a resilient, scientifically robust platform that supports faster, more reliable translation of preclinical findings into clinical investigation.

Robust triangulation approach combining primary stakeholder intelligence, laboratory validations, operational audits, and curated secondary evidence to ensure rigorous actionable conclusions

The research methodology underpinning this executive synthesis combines qualitative primary engagement, targeted operational validation, and curated secondary evidence to ensure findings are both rigorous and directly applicable. Primary inputs included structured interviews with senior translational scientists, operational leaders, and procurement specialists to capture first-hand perspectives on model selection, vendor performance, and logistics challenges. These interviews were complemented by operational audits and lab visits that validated workflows, model breeding programs, and data capture processes, providing on-the-ground confirmation of reported capabilities.

Secondary evidence was assembled from open literature, technical white papers, and regulatory guidance documents to contextualize technological trends and evolving best practices. To ensure reliability, findings were triangulated across multiple sources and checked for internal consistency; where divergent perspectives emerged, follow-up queries were used to reconcile differences and to clarify the operational implications. Quality control procedures included protocol traceability checks, verification of assay validation status, and assessment of data management practices to confirm reproducibility claims.

By combining stakeholder insight with empirical validation and documentary review, the methodology balances depth and breadth, resulting in conclusions that are both evidence-based and pragmatic for decision-makers.

Clear conclusions synthesizing operational insights, scientific trends, and strategic implications to guide executive decision-making and near term research program optimization in oncology

This synthesis brings into focus several enduring truths for preclinical oncology research: model choice matters, operational resilience underwrites translational confidence, and integrated data practices shorten the path from experimental observation to program decision. Scientific progress in immuno-oncology and targeted therapeutics demands tailored in-vivo strategies that reflect mechanism of action, dosing route, and clinical endpoints. At the same time, external pressures-ranging from trade measures to regional regulatory variation-require that sponsors and providers alike invest in diversified sourcing, localized capabilities, and stronger contractual frameworks.

Looking ahead, organizations that harmonize scientific rigor with operational discipline will be best positioned to de-risk early development and to deliver reproducible, clinically meaningful data. This requires a sustained focus on capability building, cross-functional alignment, and strategic partnerships that enable earlier access to translational expertise. Ultimately, the combination of advanced model systems, robust quality systems, and analytics that produce decision-ready outputs will determine which programs advance with confidence and which require further iteration.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology Based In-Vivo CRO Market, by Animal Model

  • 8.1. Murine
    • 8.1.1. Genetically Engineered Mouse Model
    • 8.1.2. Immunocompetent Syngeneic
    • 8.1.3. Mouse Xenograft
  • 8.2. Non Murine
    • 8.2.1. Dog
    • 8.2.2. Rabbit
    • 8.2.3. Rat

9. Oncology Based In-Vivo CRO Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Oncology Based In-Vivo CRO Market, by Therapeutic Modality

  • 10.1. Chemotherapy
  • 10.2. Immunotherapy
    • 10.2.1. Checkpoint Inhibitors
    • 10.2.2. Monoclonal Antibodies
  • 10.3. Targeted Therapy
    • 10.3.1. Kinase Inhibitors
    • 10.3.2. Small Molecule Inhibitors

11. Oncology Based In-Vivo CRO Market, by End User

  • 11.1. Academia & Research Institute
  • 11.2. Contract Research Organization
  • 11.3. Pharmaceutical

12. Oncology Based In-Vivo CRO Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oncology Based In-Vivo CRO Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oncology Based In-Vivo CRO Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Oncology Based In-Vivo CRO Market

16. China Oncology Based In-Vivo CRO Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bioanalytical Systems, Inc.
  • 17.6. Celerion, Inc.
  • 17.7. Champion Oncology, Inc.
  • 17.8. Charles River Laboratories International, Inc.
  • 17.9. Crown Bioscience, Inc.
  • 17.10. Explora BioLabs, Inc.
  • 17.11. Frontage Laboratories, Inc.
  • 17.12. GenScript Biotech Corporation
  • 17.13. GenScript ProBio Co., Ltd.
  • 17.14. Inotiv, Inc.
  • 17.15. JSR Life Sciences Corporation
  • 17.16. KCR S.A.
  • 17.17. Laboratory Corporation of America Holdings
  • 17.18. Living Tumor Laboratory, Inc.
  • 17.19. MPI Research, Inc.
  • 17.20. Oncodesign SA
  • 17.21. Parexel International Corporation
  • 17.22. PRA Health Sciences, Inc.
  • 17.23. Syneos Health, Inc.
  • 17.24. Taconic Biosciences, Inc.
  • 17.25. The Jackson Laboratory, Inc.
  • 17.26. Toxikon Corporation
  • 17.27. Translational Drug Development, Inc.
  • 17.28. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GENETICALLY ENGINEERED MOUSE MODEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOCOMPETENT SYNGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MOUSE XENOGRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY DOG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RABBIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY RAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ANIMAL MODEL, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY MURINE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY NON MURINE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ONCOLOGY BASED IN-VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)